Trial Profile
Phase II Trial of the Immune Checkpoint Inhibitor Nivolumab in Patients With Recurrent Select Rare CNS Cancers
Status:
Recruiting
Phase of Trial:
Phase II
Latest Information Update: 23 Jan 2024
Price :
$35
*
At a glance
- Drugs Nivolumab (Primary)
- Indications CNS cancer; Ependymoma; Germ cell and embryonal neoplasms; Glioma; Gliosarcoma; Medulloblastoma; Meningioma; Papilloma
- Focus Therapeutic Use
- 13 Jan 2023 Planned End Date changed from 21 May 2024 to 21 Apr 2027.
- 13 Jan 2023 Planned primary completion date changed from 22 May 2023 to 21 Apr 2026.
- 17 Feb 2022 Planned primary completion date changed from 31 May 2023 to 22 May 2023.